Partner Headlines - AMRN

  1. Week Concludes With S&P 500 Below 2,000; Dow Below 17,000

    Benzinga
  2. Dow Falls Over 100 Points; Ulta Salon Shares Jump After Earnings ...

    Benzinga
  3. Conversant Shares Rise On Acquisition News; Health Care REIT ...

    Benzinga
  4. Markets Drop; Darden Adjusted Profit Beats Street View

    Benzinga
  5. Morning Market Losers

    Benzinga
  6. Amarin Moves Higher On Speculation Of Special Protocol Assessment

    Benzinga
  7. Top Performing Industries For June 12, 2014

    Benzinga
  8. FDA Approvals And Changes For The Week Ending February 14, 2 ...

    Benzinga
  9. Amarin Announces FDA DMEP Does Not Plan to Re-instate ANCHOR ...

    Benzinga
  10. Benzinga's Top #PreMarket Losers

    Benzinga
  11. Amarin Announces FDA Review Division Response on ANCHOR SPA Agreement ...

    Benzinga
  12. FDA Delays Decision on Amarin's Vascepa Drug

    Benzinga
  13. Amarin Receives FDA Notification That Action on ANCHOR sNDA Review ...

    Benzinga
  14. Amarin's Vascepa: Too Limited A Market Or FDA Blunder?

    Benzinga
  15. Amarin Announces Notification of Patent Allowances Related to ...

    Benzinga
  16. New Statin Rules: Which Drugmakers Had Ties?

    YCharts
  17. Is Amarin’s Fish Oil Blockbuster Dream Kaput?

    YCharts
  18. UPDATE: Citigroup Upgrades Amarin on Valuation

    Benzinga
  19. Benzinga's Top Upgrades

    Benzinga
  20. Aegis Capital Corp. Reiterates on Amarin Corporation plc After ...

    Benzinga
  21. Market Wrap For Thursday, October 17: S&P Record High On Debt ...

    Benzinga
  22. Mid-Day Market Update: SanDisk Surges On Upbeat Results; IBM ...

    Benzinga
  23. Mid-Morning Market Update: Markets Open Lower; Goldman Sachs ...

    Benzinga
  24. Stocks Hitting 52-Week Lows

    Benzinga
  25. UPDATE: Aegis Capital Downgrades Amarin Following Negative Panel ...

    Benzinga
  26. Benzinga's Top Pre-Market Losers

    Benzinga
  27. Amarin Announces Negative FDA Advisory Committee Outcome for ...

    Benzinga
  28. Amarin Halted Ahead of FDA Advisory Committee to Review sNDA ...

    Benzinga
  29. Aegis Says FDA's Outlook 'Not As Negative As People Think' on ...

    Benzinga
  30. Aegis Capital Reiterates Buy on Amarin Corporation Following ...

    Benzinga
  31. Jefferies Reiterates Buy on Amarin Corporation on Continued Positive ...

    Benzinga
  32. Goldman Sachs Reiterates Neutral on Amarin Ahead of Advisory ...

    Benzinga
  33. Amarin Shares Up 5% as FDA Says October 16th Advisory Committee ...

    Benzinga
  34. Enrollment in Amarin REDUCE-IT Cardiovascular Outcomes Study ...

    Benzinga
  35. Amarin Reports 30th Patent for Vascepa

    Benzinga
  36. Amarin Submits Supplemental NDA for Novasep as Fourth Vascepa ...

    Benzinga
  37. UPDATE: Citigroup Raises PT on Amarin Following Lighter 2Q13 ...

    Benzinga
  38. UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership ...

    Benzinga
  39. Amarin Announces USPTO Allowance for Application 13/614,129 Related ...

    Benzinga
  40. Amarin Announces Patent Allowance Related to Vascepa and FDA ...

    Benzinga
  41. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus
  42. Benzinga's Top Pre-Market Gainers

    Benzinga
  43. Amarin Completes Dosing in a Fixed-Dose Combination Study With ...

    Benzinga
  44. Amarin Closes Dosing in Fixed-Dose Combination Study with Vascepa

    Benzinga
  45. FDA's Orange Book Doesn't Include Amarin's Vascepa NCE Status ...

    Benzinga
  46. Benzinga's Top Pre-Market Gainers

    Benzinga
  47. Amarin Receives Patent Allowance for Application 13/623,450 Related ...

    Benzinga
  48. Amarin Announces David Stack Appointed to Board of Directors

    Benzinga
  49. Amarin Spikes Lower

    Benzinga
  50. UDPATE: Aegis Capital Raises PT on Amarin to $35

    Benzinga
  51. Citigroup Reiterates Buy Rating, $20 PT on Amarin Corporation

    Benzinga
  52. Benzinga's Top Pre-Market Losers

    Benzinga
  53. UPDATE: Citigroup Initiates Amarin at Buy on Vascepa Overhang ...

    Benzinga
  54. Benzinga's Top Pre-Market Gainers

    Benzinga
  55. Amarin Awarded Patent 8,318,715 for Vascepa by USPTO

    Benzinga
  56. Amarin Announces USPTO has Published Notification of Notice of ...

    Benzinga
  57. A Peek Into The Market Before The Trading Starts

    Benzinga
  58. Amarin Announces US Patent 8,314,086 Award for Vascepa

    Benzinga
  59. Mid-Morning Market Update: Markets Rallying; J.C. Penney Misses ...

    Benzinga
  60. Amarin Awarded US Patent 8,298,554 Issuance for Vascepa

    Benzinga
  61. UPDATE: Wedbush Securities Downgrades Amarin Corporation to Neutral, ...

    Benzinga
  62. Benzinga's M&A Chatter for Tuesday September 11, 2012

    Benzinga
  63. Benzinga's M&A Chatter for Thursday September 6, 2012

    Benzinga
  64. Amarin Announces Notification of Patent Allowances for U.S. Applications ...

    Benzinga
  65. Amarin Announces Notification of Patent Allowance for Vascepa ...

    Benzinga
  66. Amarin Announces Additional Publication of MARINE Phase 3 Clinical ...

    Benzinga
  67. Health Care Sector Wrap

    FoxBusiness
  68. Benzinga's Top Pre-Market Gainers

    Benzinga
  69. Health Care Sector Wrap

    FoxBusiness
  70. Health Care Sector Wrap

    FoxBusiness
  71. Amarin Corporation (AMRN) Sees Spike in Option Activity with ...

    MarketIntelligenceCenter
  72. Amarin's

    IBD
  73. Facebook Inc. - Class A, Starbucks Among Stocks Down on High ...

    FoxBusiness
  74. Amarin Announces FDA Approval of Vascepa Capsules for the Reduction ...

    Benzinga
  75. Amarin and Horizon Pharma Higher Ahead of PDUFA Dates

    Benzinga
  76. Health Care Sector Wrap

    FoxBusiness
  77. Amarin Responds to Erroneous Website Posting

    Benzinga
  78. Biotechs With Upcoming PDUFA Dates

    Benzinga
  79. UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, ...

    Benzinga
  80. New Annual Highs: AMRN, DIS, and NWS

    SchaeffersResearch
  81. Health Care Sector Wrap

    FoxBusiness
  82. Amarin (AMRN) Gains 10.5% As Company Appears Close to Winning ...

    MarketIntelligenceCenter
  83. Amarin Corporation plc, Loral Space & Communications Gapping ...

    FoxBusiness
  84. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT ...

    Benzinga
  85. CF Industries Holdings, SBA Communications Corporation Included ...

    FoxBusiness
  86. AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus ...

    Benzinga
  87. Amarin Corporation plc (AMRN) Sees Above Average Option Activity ...

    MarketIntelligenceCenter
  88. Earnings Scheduled For May 8

    Benzinga
  89. Amarin

    IBD
  90. Amarin (AMRN) Up 20% on Patent News, Analyst Commentary

    MarketIntelligenceCenter
  91. Amarin Up 7% After FDA Announces it Will Not Convene FDA Panel ...

    Benzinga
  92. AMRN said the FDA accepted a new drug for review, while OII updated ...

    SchaeffersResearch
  93. Benzinga's M&A Chatter for Tuesday December 6, 2011

    Benzinga
Trading Center